Raymond James maintains Strong Buy on Liquidia stock, $29 target

Raymond James reaffirmed its Strong Buy rating with a $29 price target for Liquidia Technologies (LQDA) after the FDA approved Yutrepia for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The approval coincides with the expiration of Tyvaso DPI's exclusivity and precedes Liquidia's webcast on its commercialization strategy; analysts forecast substantial sales growth, citing Yutrepia's potential, particularly in PH-ILD, as supported by data from the ASCENT trial, with BTIG, Scotiabank, and Needham also reiterating positive ratings.

Analysis

Liquidia Technologies (NASDAQ:LQDA) has received a significant endorsement with Raymond James reaffirming its Strong Buy rating and a $29.00 price target, following the U.S. Food and Drug Administration's (FDA) final approval for Yutrepia. This approval, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), strategically arrived as Tyvaso DPI's NCI exclusivity expired and just before the PDUFA target date. Despite a recent 10% pullback, LQDA shares have surged 32% over the past six months, currently trading at $15.35, with analyst targets ranging broadly from $13 to $36 and a strong consensus recommendation of 1.7. The approved drug label for Yutrepia met expectations, with potential for future amendment based on favorable tolerability data from the ASCENT study, particularly for PH-ILD patients at higher doses than Tyvaso DPI. This positive clinical data, recently presented at the American Thoracic Society conference, has also led to reiterated Buy/Outperform ratings from BTIG ($29 target), Scotiabank ($36 target), and Needham ($25 target), all highlighting Yutrepia's therapeutic potential and market opportunity. Liquidia, which possesses a healthy current ratio of 2.93 and moderate debt levels, is poised for substantial sales growth, according to analyst forecasts. The company plans to outline its commercialization strategy for Yutrepia, initially submitted for NDA in January 2020, in a webcast on May 27, with management previously indicating a potential market distribution within 2-3 weeks post-approval.

Key Decisions for Investors

• Investors should consider the FDA approval of Yutrepia and strong analyst consensus as significant positive catalysts, potentially viewing the recent 10% stock pullback as a revised entry point.
• Closely monitor Liquidia's upcoming webcast on May 27 for critical details regarding Yutrepia's commercialization strategy and initial market launch timelines, which are expected within weeks.
• Evaluate the potential for future label expansion based on the ASCENT trial data as an additional upside driver, particularly for the PH-ILD indication.
• Factor in the forecasted substantial sales growth and the drug's competitive positioning against existing treatments when assessing Liquidia's long-term value proposition.